With a legacy stretching back to 1983, Advarra® is the premier provider of institutional review board (IRB), institutional biosafety committee (IBC), and research quality and compliance consulting services in North America. Fully accredited by AAHRPP, Advarra serves the world’s leading pharmaceutical, biotechnology, medical device, and contract research organizations, as well as academic medical centers, health systems, investigative site networks, and therapeutic research consortia.
To address the increasingly complex needs associated with research, Advarra leverages exceptional client service, innovative technology, and robust global regulatory expertise. Advarra also provides deep experience across all major therapeutic areas and continues to pioneer highly specialized review services for areas such as oncology.
Advarra’s extensive geographic reach helps clients navigate an evolving research and regulatory environment.
Above all, Advarra provides integrated compliance services with unprecedented clarity, helping you navigate regulatory requirements more confidently.
Advance human health by empowering compliant, efficient, and collaborative research.
Be the global partner of choice to achieve compliance and streamlined operations across the research continuum.
Advarra brings together the industry’s three most respected IRBs for service and efficiency. Initially formed in 2017 through the merger of Chesapeake IRB and Schulman IRB, Advarra added Quorum Review IRB and its consulting division, Kinetiq, to the organization in 2019. Advarra is pioneering an integrated approach to IRB, IBC, and research compliance consulting services. We do so by leveraging our strengths in technology, regulatory expertise, and customer service to address the increasingly complex needs associated with research.
Advarra sets the standard in quality, easy document accessibility, and review turnaround time. We have enhanced our paperless, cloud-based submission and review platform, the Advarra Center for IRB Intelligence (CIRBI®) Platform. Additionally, we are a leader in the protection of human research participants with expert therapeutic review services including Central Oncology Review (COR).